H Kajiyama


Affiliation: Nagoya University
Country: Japan


  1. Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Yamamoto E, et al. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?. Int J Gynecol Cancer. 2012;22:394-9 pubmed publisher
    ..300/1.498; 95% confidence interval [CI], 1.039-1.626/1.197-1.874). Despite the continuous administration of treatment for ROC, survival is poor, and the extent of therapeutic progress differs according to the histological type. ..
  2. Kajiyama H, Suzuki S, Utsumi F, Yoshikawa N, Nishino K, Ikeda Y, et al. Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma. Int J Clin Oncol. 2019;: pubmed publisher
    ..654), P = 0.0036]. The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy. ..
  3. Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Shibata K, Nagasaka T, et al. Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary. Int J Gynecol Cancer. 2019;: pubmed publisher
    ..114). Patients with intraperitoneal recurrence or incomplete tumor resection had the worst survival after secondary cytoreductive surgery. ..
  4. Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, et al. A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. Int J Clin Oncol. 2014;19:921-7 pubmed publisher
    ..394; 95 % CI, 1.445-61.070; P = 0.0190]. We should keep in mind the greater risk of recurrence in patients with stage IC disease or higher, other than those stage IC patients with intraoperative rupture. ..
  5. Kajiyama H, Suzuki S, Niimi K, Tamauchi S, Kawai M, Nagasaka T, et al. Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer. Int J Clin Oncol. 2019;: pubmed publisher
    ..It is desirable to verify the utility by accumulating larger numbers of patients through a future registry system. ..
  6. Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Nagasaka T, Kikkawa F. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study. Eur J Obstet Gynecol Reprod Biol. 2019;234:131-136 pubmed publisher
    ..IC1: HR (95% CI): 3.527 (1.125-12.568), P = 0.0300)}. mEOC patients staged greater than IC1 show a marked risk of mortality even after postoperative chemotherapy. ..
  7. Yoshida K, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, et al. Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?. Int J Clin Oncol. 2019;24:567-574 pubmed publisher
    ..558]. Moreover, Kaplan-Meier curves showing post-recurrence survival revealed no significant difference between the two groups (P = 0.141). Prophylactic para-aortic lymph nodes irradiation did not reduce the risk of recurrence. ..
  8. Kajiyama H, Suzuki S, Yoshihara M, Tamauchi S, Yoshikawa N, Niimi K, et al. Endometriosis and cancer. Free Radic Biol Med. 2019;133:186-192 pubmed publisher
  9. Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, et al. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2012;22:801-6 pubmed publisher
    ..8%; RSAC, 40.7%; [P < 0.0001]). The long-term clinical outcome of patients with RCCC was extremely poor. We confirmed that RCCC should be investigated as a different malignancy compared with RSAC. ..

More Information


  1. Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, et al. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018;219:385.e1-385.e7 pubmed publisher
    ..The reproductive outcomes of malignant ovarian germ cell tumor survivor are promising with fertility-sparing treatment. Malignant ovarian germ cell tumor survivors can become pregnant and give birth if they desire. ..
  2. Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, et al. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?. Eur J Obstet Gynecol Reprod Biol. 2014;181:305-10 pubmed publisher
    ..0343: clear-cell/mucinous (vs. non- clear-cell/mucinous): HR: 2.486(95% CI: 1.416-4.364), P=0.0015). Even if at stage I, once patients with a mucinous/clear-cell histology experience recurrence, subsequent survival is extremely poor. ..
  3. request reprint
    Kajiyama H, Hosono S, Terauchi M, Shibata K, Ino K, Yamamoto E, et al. Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology. 2006;71:394-401 pubmed
    ..0077 and 0.0033, respectively). The current findings suggest that the assessment of Twist immunoreactivity may be a useful prognostic indicator and that Twist may play a critical role in the progression of CCC. ..
  4. Kajiyama H, Shibata K, Suzuki S, Ino K, Nawa A, Kawai M, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36:404-8 pubmed publisher
    ..030, and DFS; P=0.005, respectively}. Thirteen pregnancies were observed in 9 patients. FSS may be considered a treatment option in women with stage I EOC, even in those with stage IC(capsule rupture) or more wishing to bear children. ..
  5. Kajiyama H, Shibata K, Suzuki S, Ino K, Yamamoto E, Mizuno K, et al. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?. Gynecol Oncol. 2008;111:523-6 pubmed publisher
    ..Although there is no worldwide criterion for FSS in CCC patients at present, it seems that, in selected patients, this surgical approach could be adopted. This should be investigated by additional studies in a larger series. ..
  6. Koya Y, Kajiyama H, Liu W, Shibata K, Senga T, Kikkawa F. Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells. J Vis Exp. 2016;: pubmed publisher
    ..This proposed method is a less invasive procedure for the mouse and minimizes damage to the ovary. Here, we describe the methodological steps in the development of the original and metastatic tumor formation of EOC. ..
  7. Sugiyama K, Kajiyama H, Shibata K, Yuan H, Kikkawa F, Senga T. Expression of the miR200 family of microRNAs in mesothelial cells suppresses the dissemination of ovarian cancer cells. Mol Cancer Ther. 2014;13:2081-91 pubmed publisher
    ..Our results suggest that alteration of the tumor microenvironment by the miR200 family could be a novel therapeutic strategy for ovarian cancer treatment. ..
  8. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, et al. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007;7:140 pubmed
    ..The current data indicate the possible involvement of APN/CD13 in the development of OVCA, and suggest that clinical use of bestatin may contribute to better prognosis for ovarian carcinoma patients. ..
  9. Nakamura K, Peng Y, Utsumi F, Tanaka H, Mizuno M, Toyokuni S, et al. Novel Intraperitoneal Treatment With Non-Thermal Plasma-Activated Medium Inhibits Metastatic Potential of Ovarian Cancer Cells. Sci Rep. 2017;7:6085 pubmed publisher
    ..Our findings suggest that PAM intraperitoneal therapy may be a promising treatment option for ovarian cancer. ..
  10. Kajiyama H, Shibata K, Ino K, Mizutani S, Nawa A, Kikkawa F. The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci. 2010;101:347-54 pubmed publisher
    ..In contrast, on Day 61, the former was smaller than the latter. The present findings show that DPPIV may be involved in the increased sensitivity to paclitaxel of EOC cells regardless of the involvement of DPPIV activity. ..
  11. request reprint
    Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer. 2008;122:91-9 pubmed
    ..The present results suggest that there may be a link between the SDF-1alpha/CXCR4 axis and enhanced intraperitoneal dissemination of EOC and that CXCR4 may be a novel target for the treatment of EOC...
  12. request reprint
    Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Possible involvement of SDF-1alpha/CXCR4-DPPIV axis in TGF-beta1-induced enhancement of migratory potential in human peritoneal mesothelial cells. Cell Tissue Res. 2007;330:221-9 pubmed
    ..These results suggest that DPPIV and SDF-1alpha/CXCR4 play crucial roles in regulating the migratory potential of HPMCs, which may be involved in the re-epithelialization of denuded basement membrane at the site of peritoneal injury. ..